1. A novel prognostic nomogram utilizing the 2018 FIGO staging system for cervical cancer: A large multicenter study
- Author
-
Songping Liu, Junjun Qiu, Keqin Hua, Chenyan Guo, Jingjing Guo, and Xiaoyan Tang
- Subjects
medicine.medical_specialty ,Uterine Cervical Neoplasms ,Lymph node metastasis ,03 medical and health sciences ,0302 clinical medicine ,Figo staging ,medicine ,Humans ,030212 general & internal medicine ,Stage (cooking) ,Neoplasm Staging ,Retrospective Studies ,Cervical cancer ,030219 obstetrics & reproductive medicine ,Tumor size ,business.industry ,Parametrial ,Obstetrics and Gynecology ,General Medicine ,Nomogram ,Prognosis ,medicine.disease ,Nomograms ,Multicenter study ,Female ,Radiology ,business - Abstract
OBJECTIVE To evaluate the prognostic performance of the revised 2018 FIGO staging system for cervical cancer. METHODS This retrospective multicenter study enrolled cervical cancer patients with 2009 FIGO Stage IA1-IIA2 who underwent surgeries between January 2006 and December 2017 in four tertiary hospitals. Patients were restaged according to the 2018 FIGO staging system by reviewing their medical data. RESULTS Of 3238 cervical cancer patients included, 1841 (56.9%) patients were restaged: 641 (34.9%) due to tumor size, 544 (29.5%) due to lymph node metastasis, 614 (33.4%) due to the inconsistency between pre- and postoperative assessments, and 42 due to the cancellation of invasion width in Stage IA. After restaging, a clear tendency of decreased recurrence-free survival (RFS) and overall survival (OS) with increasing stage was observed. Multivariate Cox analysis showed that 2018 FIGO stage, parametrial involvement, and histology were independent prognostic factors for both OS and RFS (P
- Published
- 2021